Wall Street dives into Neurocrine Biosciences By Investing.com

© Reuters

Explore Wall Street’s expertise in this ProResearch article, which will be available exclusively InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This new year, enjoy up to 50% off plus 10% off 2-year subscription with code research23, reserved for the first 500 fast subscribers. To ensure constant access to valuable content like this, step up your investing game with InvestingPro.

In a competitive and ever-evolving biopharmaceutical environment, Neurocrine (NASDAQ:) Biosciences, Inc. (NASDAQ: NBIX) excels in its focus on neurological and endocrine diseases and disorders. Analysts have closely monitored the company’s performance and developments, providing insights that are key for investors seeking to understand the potential risks and rewards associated with NBIX.

Performance in different markets

Neurocrine Biosciences’ core product, Ingrezza, which is used to treat tardive dyskinesia, continues to perform solidly, though there have been concerns that its long-term potential is not meeting the Street’s expectations despite its short-term durability. The company’s focus on diversifying its revenue base is marked by R&D efforts, with multiple Phase 2 readouts expected in 2024 and several Phase 1 initiations planned for its muscarine portfolio.

Product segments and pipelines

Neurocrine’s pipeline is a mix of promise and failure. “20 in 5” aims to produce 20 development candidates over the next five years, which should also improve their ability to evaluate external business development opportunities. The recent success of crinecerfont in phase III trials for congenital adrenal hyperplasia (CAH) was a silver lining and potentially set the stage for a new blockbuster. Neurocrine expects significant catalysts in 2024 that could de-risk its historically risky pipeline, including five major Phase 2 reports. A strong patient network for CAH suggests a potentially robust launch for crinecerfont due to the lack of available therapies.

Competitive environment and market trends

Neurocrine operates in a highly competitive market where innovation and timely product development are key. The diversity we’re about to position Neurocrine to be competitive in the neurology space, with speculation of new treatments and strategic acquisitions to fuel its growth. Analysts also see the company as a potential acquisition target in its own right, given its strong Ingrezza product and promising pipeline candidates.

Regulatory environment and customer base

The regulatory environment remains a critical factor for Neurocrine. The company has received breakthrough status for CAH, a major milestone that could accelerate its drug development process. Analysts expect the company to pass these milestones effectively, which could lead to significant value appreciation.

Management and strategy

Under new leadership, Neurocrine is refocusing on proven biology and lower-risk innovation. The strategic pivot is expected to capitalize on the company’s core strengths and improve its risk profile, reflecting analysts’ maintained “Overweight” rating.

External factors

The Inflation Reduction Act (IRA) continues to be of concern to analysts, with potential impacts on Ingrezza’s long-term prospects due to changes in drug pricing and reimbursement. In addition, entering the long-term care (LTC) market is associated with high costs.

Upcoming product launches

Crinecerfont’s upcoming launch after likely approval in late 2024 is highly anticipated. The drug’s potential to treat CAH could position it as a standard treatment with significant market share.

Stock performance

Shares of Neurocrine have fluctuated in response to pipeline developments and market conditions. Analysts have provided different price targets that reflect their individual assessments of the company’s risk-reward scenario and future prospects.

Bear case

Does Neurocrine Biosciences Face Significant Risks?

Despite a broad spectrum of actives targeting muscarinic mechanisms and the potential for success, Neurocrine has experienced setbacks, notably the failure of ‘352 for epilepsy and ‘864 for anhedonia. These failures limit the company’s ability to diversify outside of Ingrezza, raising concerns about its long-term growth potential. Analysts adjusted their price targets accordingly in light of heightened risk perception and the need for strategic decisions to rebuild the pipeline.

Will Neurocrine’s reliance on Ingrezza affect its growth prospects?

While strong sales of Ingrezza continue, there is skepticism about the drug’s ability to sustain long-term growth, especially with the potential impact of IRAs. The company’s reliance on this single product could pose a risk to its valuation if pipeline development does not yield successful new treatments.

Bull Case

Can Neurocrine Biosciences capitalize on its recent clinical successes?

The success of crinecerfont in the Phase III CAH trials was a significant boost for Neurocrine. Analysts believe the drug has the potential to become a standard treatment for CAH with a high likelihood of regulatory approval. The company’s strategic acquisitions and focus on low-risk innovation could further strengthen its growth trajectory.

Is the Market Underestimating Potential Neurocrine Catalysts?

Upcoming catalysts, including Phase II readouts for ‘352 in focal seizures and the muscarinic program, could provide significant improvements for Neurocrine. Analysts remain optimistic about the company’s ability to deliver on these fronts, which could lead to an overvaluation of NBIX stock.

SWOT analysis


– Strong sales performance of Ingrezza.

– Positive Phase III study results for crinecerfont in CAH.

– Strategic focus on low-risk innovation and proven biology.


– Pipeline failures with two programs failing mid-stage.

– Heavy reliance on Ingrezza for revenue.

– The potential impact of IRAs on long-term prospects.


– Market expansion through strategic acquisitions.

– Upcoming product launches and pipeline readings.

– Untapped market potential for the treatment of tardive dyskinesia.


– Competitive market with rapid innovation.

– Regulatory hurdles and insurance issues.

– Implementation risks when introducing new products to the market.

Objectives of the analyst

– Barclays Capital Inc.: Overweight rating with a price target of $125.00 (December 7, 2023).

– BMO Capital Markets Corp.: Rating Market Perform with a price target of $100.00 (December 6, 2023).

– RBC Capital Markets: Sector Perform rating with a price target of $128.00 (November 1, 2023).

– Piper Sandler: Neutral rating with $100.00 price target (November 1, 2023).

The time frame of the analysis is from September to December 2023.

InvestingPro statistics

Since Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) is going through a dynamic biopharma market, its financial health and stock performance are key areas of interest for investors. According to real-time data from InvestingPro, Neurocrine’s market capitalization is at par 12.81 billion USD, indicating a significant presence in the industry. A company’s P/E ratio, a measure of a stock’s current price relative to its earnings per share, is 41.8 on an adjusted basis over the trailing twelve months from Q3 2023, indicating that investors expect future earnings growth.

InvestingPro Tips highlights that Neurocrine is trading at a low P/E ratio given its near-term earnings growth, which could be an attractive point for those looking for value in the stock market. In addition, the company is recognized for its high return on invested capital, which is an indicator of efficiency in allocating capital to profitable investments.

For those looking for more information, InvestingPro offers plenty of other picks, with 18 listed just for Neurocrine Biosciences. These tips can provide a deeper understanding of a company’s financial health and market position. Subscribers can access these statistics and other information when they visit InvestingPro’s dedicated Neurocrine page.

For investors interested in a comprehensive investment tool, InvestingPro is currently offering a Cyber ​​Monday special with discounts of up to 60%. Plus, use the coupon code research23 for an extra 10% discount for 2 years InvestingPro+ a subscription to ensure you have the most up-to-date and useful market data at your fingertips.

This article was created with AI support and reviewed by an editor. See our T&C for more information.